Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Is ALNY a good investment?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 71.0/100 as of October 12, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG ratio 0.53 vs. industry average 1.69 — 69% growth-adjusted discount to biotech peers, with 5-year forward EPS CAGR of 74.8% being 3.4x the industry average 21.8%; at current P/E of 39.28x against 74.8% growth, stock trades at roughly half its intrinsic value under a PEG-parity framework (~$443/share implied, analyst consensus $346.92 implies 49.1% upside). Main concern: ATTR franchise double-hit — (1) AstraZeneca/Ionis CARDIO-TTRansform trial failure caused ~18% ALNY sympathy selloff raising investor doubt about ATTR-CM market validity, and (2) Alnylam itself cut full-year revenue guidance citing slower-than-expected Amvuttra sales — these two events together represent a meaningful reset of the flagship revenue growth assumption and constitute a material worsening since the prior report; this is the most critical near-term risk.
Investment Summary
Alnylam Pharmaceuticals (ALNY) at $232.68 presents a fundamentally exceptional but news-pressured biotech investment. The stock has declined 9.1% from our prior report ($255.96 → $232.68), driven by two compounding negatives: (1) the AstraZeneca/Ionis CARDIO-TTRansform trial failure that dragged ALNY shares down ~18% on ATTR-CM franchise risk contagion, and (2) Alnylam's own cut to full-year revenue guidance citing slower-than-expected Amvuttra sales. The securities fraud investigation remains active with multiple law offices seeking class members. Against these headwinds, the fundamentals remain elite: PEG of 0.53 (vs. industry 1.69, a 69% discount), operating margin of +17.9% vs. industry average of -91.9% (+109pp advantage), 5-year forward EPS CAGR of 74.8% (3.4x the industry average of 21.8%), FCF of $542.5M, and $3.31B cash. Analyst consensus target of $346.92 implies 49.1% upside from current prices. The investment case remains intact but the near-term news environment — guidance cut, competitor trial failure creating sentiment overhang on ATTR franchise, active litigation — demands a discounted entry and reduced conviction relative to pure fundamentals.
Key Strengths
- PEG ratio 0.53 vs. industry average 1.69 — 69% growth-adjusted discount to biotech peers, with 5-year forward EPS CAGR of 74.8% being 3.4x the industry average 21.8%; at current P/E of 39.28x against 74.8% growth, stock trades at roughly half its intrinsic value under a PEG-parity framework (~$443/share implied, analyst consensus $346.92 implies 49.1% upside)
- Profitability leadership unmatched in 132-company peer group: operating margin +17.9% vs. industry -91.9% (+109pp), net margin 16.8% vs. industry 0.38% (44x), ROE 100.7% vs. industry -3.7% — FCF of $542.5M and $3.31B cash make ALNY one of the only truly self-funding commercial biotechs in a peer group dominated by cash burners requiring continuous dilutive equity raises
- Pipeline diversification provides multiple shots on goal beyond ATTR franchise: zilebesiran (RNAi hypertension, ZENITH trial targeting large cardiovascular TAM) reduces binary event risk; 18 of 21 analysts maintain Buy ratings despite recent headwinds, confirming institutional conviction in long-duration compounding thesis
Key Concerns
- ATTR franchise double-hit — (1) AstraZeneca/Ionis CARDIO-TTRansform trial failure caused ~18% ALNY sympathy selloff raising investor doubt about ATTR-CM market validity, and (2) Alnylam itself cut full-year revenue guidance citing slower-than-expected Amvuttra sales — these two events together represent a meaningful reset of the flagship revenue growth assumption and constitute a material worsening since the prior report; this is the most critical near-term risk
- Active securities fraud class action investigation (multiple law firm headlines visible in current news feed — 'Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues...' appearing multiple times) creates ongoing litigation overhang, institutional hesitation, and potential financial liability; combined with D/E of 1.98 (9.2x industry average 0.22), any further earnings disappointment amplifies downside through both multiple compression and balance sheet narrative deterioration
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ALNY's fundamentals remain top-decile. Gross margin 79.7% (vs. industry avg 79.8% — at parity with best-in-class peers). Operating margin +17.9% vs. industry average -91.9%, a 109.9pp advantage confirming ALNY is one of the rare commercially mature biotechs. Net margin 16.8% vs. industry 0.38% (+4,315% relatively). ROE 100.7% vs. industry -3.7% — extraordinarily high, partially leverage-amplified (D/E 1.98 vs. industry avg 0.22 — ALNY carries 9.2x peer leverage). P/E of 39.28 appears elevated but PEG of 0.53 (industry avg 1.69, -69% discount) signals deep growth-adjusted undervaluation — a PEG-implied fair P/E using the 74.8% 5-year EPS CAGR would be ~74.8x, suggesting intrinsic value near $443/share, or conservatively ~$347 at analyst consensus. P/B of 22.98 is justified by 100.7% ROE. Revenue growth 66.9% from a large base. FCF $542.5M validates earnings quality — no accounting artifacts. Cash $3.31B provides multi-year runway. Financial health concern: D/E 1.98 vs. industry 0.22 (820% above peers) is the primary balance sheet vulnerability, but FCF serviceability mitigates near-term default risk. Next-year EPS growth 51.1% lags industry avg 89.5%, but 5-year CAGR of 74.8% (3.4x industry 21.8%) dominates the long-duration thesis.
News Sentiment
Alnylam Pharmaceuticals finds itself navigating one of the roughest stretches in its commercial history, with a cascade of bad news testing investor patience in the RNA interference pioneer. The company's flagship drug Amvuttra hit a speed bump this year when Alnylam was forced to cut its full-year revenue guidance, citing slower patient uptake than Wall Street had expected — a gut punch for a stock that commands a premium valuation based on explosive growth promises. Then came more trouble from an unexpected source: rival AstraZeneca and Ionis Pharmaceuticals saw their CARDIO-TTRansform heart disease trial stumble, and Alnylam shareholders paid the price — shares tumbled roughly 18% as investors worried the failure cast doubt on the entire ATTR heart disease treatment category that Alnylam has bet big on. Adding to the headache, multiple law firms are actively investigating Alnylam for potential securities fraud, with repeated announcements seeking shareholders who lost money — a legal cloud that makes big institutional investors nervous. Yet amid the gloom, some analysts are pointing out that Alnylam may be oversold. One headline — 'Alnylam vs. Ionis: Here's the Better Bad-News Buy' — captures the contrarian view: even with the setbacks, Alnylam's underlying business generates real profits and $542 million in annual free cash flow, a rarity in biotech. Meanwhile, former athlete patient stories for Amvuttra suggest the marketing machine is still running. The question for investors: is this a buying opportunity or a falling knife?
Risk Assessment
PRIMARY RISK: ATTR franchise deterioration — the combination of competitor trial failure (AZ/Ionis CARDIO-TTRansform) creating category-level doubt AND Alnylam's own guidance cut for Amvuttra creates a compounding negative narrative around the flagship asset. If ATTR-CM patient adoption continues to disappoint, the 74.8% 5-year EPS CAGR assumption collapses and the PEG-based valuation thesis unravels — a de-rated P/E of 25x on revised earnings could imply $150-170/share. SECONDARY RISK: Securities fraud litigation — financial liability uncertain, institutional ownership suppressed during investigation, headline risk from ongoing law firm announcements. TERTIARY RISK: D/E of 1.98 (9.2x industry average) means any earnings revision simultaneously compresses the multiple AND raises debt serviceability questions, creating a double-negative feedback. MITIGATION: $3.31B cash cushion provides 5+ years of operational runway; FCF of $542.5M is real and covers debt service; 18/21 analyst Buys with $346.92 target confirm that sophisticated institutional analysis supports the thesis; zilebesiran hypertension pipeline represents a massive TAM uncorrelated to ATTR that could re-rate the stock independent of TTR outcomes. Position size reduced to 2.0% (from 2.5% prior) to reflect the worsening near-term news.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ALNY a halal stock?
No, Alnylam Pharmaceuticals, Inc. (ALNY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 71.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ALNY a good investment?
According to Plutrex AI, ALNY has a Buy rating (71.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ALNY?
US stocks like ALNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ALNY?
Plutrex AI identifies the main risks for ALNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.